CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
Company has been exploring multiple acquisition and licensing opportunities, with the goal of securing first transaction by year-end$17.2 million cash position provides financial strength to support strategic execution and planned operationsHOUSTON, TX / / November 16, 2026 / CNS Ph…